SEC Form 4Coverage since Aug 18, 2025Open-market trades only
$IONS insider trading
Over the last 12 months, Ionis Pharmaceuticals insiders reported 1 buy totaling $1.1M and 89 sales totaling $157.0M across SEC Form 4 filings. 70% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $1.1M 1 event
- Sold · 12m
- $157.0M 89 events
- Events · 12m
- 90 Form 4 filings, grouped
- Insiders · 12m
- 20 distinct reporters
- 10b5-1 share
- 70% of events, not dollars
Side
Price · $IONS · 3Mvia TradingView
Top insiders · 12m
Baroldi JosephEVP, Chief Business Officer11× · $4.4M
Swayze EricEVP Research9× · $7.5M
O'NEIL PATRICK R.EVP CLO & General Counsel9× · $10.6M
Devers Shannon L.EVP, Chief Human Resources Ofc7× · $8.7M
BENNETT C FRANKEVP, Chief Scientific Officer6× · $16.7M
All insider trades
50 of 108 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Hayden Michael RD | ▲ Buy | 20,000 | $52.94 | $1.1M | +500% | 2 tranches · indirect |
| Jul 7, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer · O | ▼ Sale | 15,000 | $85.46 | $1.3M | -100% | plan · indirect |
| Jul 7, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer · O | ▼ Sale | 5,536 | $83.58 | $463K | -6.9% | plan |
| Jul 7, 2026 | Diaz Allene M.D | ▼ Sale | 10,111 | $85.42 | $864K | -72.6% | plan |
| Jul 7, 2026 | Kordasiewicz Holly B.EVP, Chief Development Officer · O | ▼ Sale | 362 | $84.3 | $31K | -1.6% | plan |
| Jul 1, 2026 | KLEIN JOSEPH IIID | ▼ Sale | 11,518 | $79.04 | $910K | -51.1% | plan · 2 tranches |
| Jun 26, 2026 | Baroldi JosephEVP, Chief Business Officer · O | ▼ Sale | 5,635 | $80.16 | $452K | -54.7% | plan · indirect |
| Jun 26, 2026 | O'NEIL PATRICK R.EVP CLO & General Counsel · O | ▼ Sale | 3,069 | $80 | $246K | -4.8% | plan |
| Jun 26, 2026 | Schneider EugeneEVP, Chf Clinical Develop Ofcr · O | ▼ Sale | 26,000 | $81.05 | $2.1M | -25.2% | plan |
| Jun 26, 2026 | Monia Brett PChief Executive Officer · O·D | ▼ Sale | 85,637 | $79.7 | $6.8M | -25.9% | plan · 3 tranches |
| Jun 25, 2026 | Swayze EricEVP Research · O | ▼ Sale | 10,602 | $79.18 | $839K | -32.8% | plan |
| Jun 15, 2026 | BERTHELSEN SPENCER RD | ▼ Sale | 8,000 | $73.49 | $588K | -4.9% | plan |
| Jun 12, 2026 | Kordasiewicz Holly B.EVP, Chief Development Officer · O | ▼ Sale | 60,846 | $73.41 | $4.5M | -73% | plan · 2 tranches |
| Jun 1, 2026 | BERTHELSEN SPENCER RD | ▼ Sale | 8,000 | $75.67 | $605K | -4.9% | plan |
| May 4, 2026 | LOSCALZO JOSEPHD | ▼ Sale | 77,289 | $75.06 | $5.8M | -68% | plan · 2 tranches |
| May 1, 2026 | KLEIN JOSEPH IIID | ▼ Sale | 10,111 | $73.51 | $743K | -47.9% | plan · 2 tranches |
| Apr 28, 2026 | Baroldi JosephEVP, Chief Business Officer · O | ▼ Sale | 1,626 | $71.79 | $117K | -3.5% | plan |
| Apr 16, 2026 | Jenne KyleEVP, Chf GL Pdt Str Ofcr · O | ▼ Sale | 4,902 | $75.17 | $368K | -17.1% | — |
| Apr 16, 2026 | Birchler BrianEVP, Corp and Development Ops · O | ▼ Sale | 973 | $75.04 | $73K | -1.4% | — |
| Apr 16, 2026 | Baroldi JosephEVP, Chief Business Officer · O | ▼ Sale | 5,619 | $74.56 | $419K | -10.8% | — |
| Apr 15, 2026 | PARSHALL B LYNNED | ▼ Sale | 5,000 | $76.27 | $381K | -8.9% | plan · 2 tranches |
| Apr 2, 2026 | Devers Shannon L.EVP, Chief Human Resources Ofc · O | ▼ Sale | 6,193 | $74.05 | $459K | -27.5% | plan |
| Apr 1, 2026 | KLEIN JOSEPH IIID | ▼ Sale | 22,321 | $75.55 | $1.7M | -67% | plan · 2 tranches |
| Mar 19, 2026 | Schneider EugeneEVP, Chf Clinical Develop Ofcr · O | ▼ Sale | 5,812 | $70.97 | $412K | -8.3% | plan |
| Mar 17, 2026 | HOUGEN ELIZABETH LEVP, Finance & CFO · O | ▼ Sale | 225,220 | $72.43 | $16.3M | -73.2% | plan · 3 tranches |
| Mar 10, 2026 | Monia Brett PChief Executive Officer · O·D | ▼ Sale | 160,773 | $75.35 | $12.1M | -39.9% | plan · 5 tranches |
| Mar 10, 2026 | Jenne KyleEVP, Chf GL Pdt Str Ofcr · O | ▼ Sale | 37,277 | $75.85 | $2.8M | -76.1% | plan · 2 tranches |
| Mar 9, 2026 | O'NEIL PATRICK R.EVP CLO & General Counsel · O | ▼ Sale | 10,148 | $75.25 | $764K | -14% | plan |
| Mar 4, 2026 | LOSCALZO JOSEPHD | ▼ Sale | 1,032 | $80.26 | $83K | -2.8% | plan · 2 tranches |
| Mar 4, 2026 | Baroldi JosephEVP, Chief Business Officer · O | ▼ Sale | 2,563 | $80.35 | $206K | -37.1% | plan · 4 tranches · indirect |
| Mar 3, 2026 | KLEIN JOSEPH IIID | ▼ Sale | 21,332 | $79.51 | $1.7M | -65.9% | plan · 3 tranches |
| Mar 3, 2026 | Diaz Allene M.D | ▼ Sale | 54,878 | $79.35 | $4.4M | -93.5% | plan · 3 tranches |
| Mar 3, 2026 | Devers Shannon L.EVP, Chief Human Resources Ofc · O | ▼ Sale | 20,106 | $79.4 | $1.6M | -47.1% | plan · 3 tranches |
| Mar 3, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer · O | ▼ Sale | 85,089 | $79.23 | $6.7M | -51.4% | plan · 3 tranches |
| Mar 3, 2026 | Baroldi JosephEVP, Chief Business Officer · O | ▼ Sale | 4,096 | $79.36 | $325K | -9% | plan |
| Feb 13, 2026 | Swayze EricEVP Research · O | ▼ Sale | 15,642 | $81.76 | $1.3M | -32.8% | plan · 2 tranches |
| Feb 11, 2026 | PARSHALL B LYNNED | ▼ Sale | 5,000 | $82.72 | $414K | -8.2% | plan |
| Feb 6, 2026 | Monia Brett PChief Executive Officer · O·D | ▼ Sale | 29,430 | $85.79 | $2.5M | -10.4% | plan |
| Feb 2, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer · O | ▼ Sale | 85,089 | $82.93 | $7.1M | -51.4% | plan · 3 tranches |
| Jan 30, 2026 | Swayze EricEVP Research · O | ▼ Sale | 6,179 | $82.93 | $512K | -11.5% | — |
| Jan 30, 2026 | Schneider EugeneEVP, Chf Clinical Develop Ofcr · O | ▼ Sale | 6,179 | $83.45 | $516K | -8.1% | — |
| Jan 30, 2026 | O'NEIL PATRICK R.EVP CLO & General Counsel · O | ▼ Sale | 6,179 | $83.53 | $516K | -7.9% | — |
| Jan 30, 2026 | Monia Brett PChief Executive Officer · O·D | ▼ Sale | 62,970 | $82.72 | $5.2M | -18.2% | — |
| Jan 30, 2026 | HOUGEN ELIZABETH LEVP, Finance & CFO · O | ▼ Sale | 6,988 | $83.24 | $582K | -5% | — |
| Jan 30, 2026 | Birchler BrianEVP, Corp and Development Ops · O | ▼ Sale | 6,179 | $83.03 | $513K | -8.5% | — |
| Jan 30, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer · O | ▼ Sale | 5,885 | $82.95 | $488K | -5.5% | — |
| Jan 30, 2026 | Baroldi JosephEVP, Chief Business Officer · O | ▼ Sale | 5,296 | $82.96 | $439K | -10.4% | — |
| Jan 22, 2026 | Devers Shannon L.EVP, Chief Human Resources Ofc · O | ▼ Sale | 3,977 | $81.34 | $323K | -15% | plan |
| Jan 16, 2026 | Swayze EricEVP Research · O | ▼ Sale | 49 | $75.97 | $4K | -13.4% | indirect |
| Jan 16, 2026 | Swayze EricEVP Research · O | ▼ Sale | 9,884 | $75.34 | $745K | -19.1% | — |
Every $IONS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Ionis Pharmaceuticals filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $IONS feed.